Tag: antibody-drug conjugate
New Phase I Study Investigates [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing...
As part of a new study focusing on advanced targeting human epidermal growth factor receptor-2 (HER2-) expressing cancers, including locally advanced or metastatic solid...
ADC Therapeutics On Track to File BLA for Loncastuximab Tesirine for...
This week Swiss-based ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for patients with hematological malignancies and...
WuXi Biologics Opens New Facility to Supports Novocodex ADC Manufacturing
Earlier this month China-based Contract Research Organization (CRO) WuXi Biologics started commercial production at the company's new Current Good Manufacturing Practice (cGMP)-approved DP3 bulk...
Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at...
Veteran Executive Randall Schatzman, Ph.D. has been hired as the new Chief Executive Officer and a member of the board of directors of Bolt...
Highlights in Development: September 2019
In September 2019, a number of articles discussing antibody-drug conjugates were published in a variety of journals. Here is an overview of some of...
Novel Payloads for Antibody-drug Conjugates
The development of antibody-drug conjugates or ADCs, has resulted in the need of developing novel compounds that can be used as payloads.
Enediynes, represented by...
ADC Biotechnology Secures Funding for Strategic move into Downstream Formulation and...
UK-based ADC Biotechnology, an innovative biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of antibody-drug conjugates, has...
Four Ways to Show Nonobviousness of ADC Inventions
As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.
Are Small-Format Drug Conjugates a Viable ADC Alternative Solid Tumors?
Antibody-drug conjugates or ADCs are complex immunoconjugates. They are designed to selectively deliver a small-molecules cytotoxic payload to cancer cells. Directed to specific tumor...
Gemtuzumab Ozogamicin Granted Positive Opinion for Treatment of Previously Untreated, De...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending that two Pfizer hematology...
